Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12674068 | 0.91 | MAPT (0.45) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL23571957 | 0.89 | TSHR (0.41) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL23109243 | 0.89 | TSHR (0.41) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL2757959 | 0.88 | TSHR (0.43) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL20953642 | 0.87 | MAPT (0.44) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL19171885 | 0.87 | TSHR (0.40) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL9126555 | 0.86 | TSHR (0.42) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL23772908 | 0.85 | TSHR (0.39) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL23109242 | 0.85 | TSHR (0.39) | TSHRLMNAMAPTPOLBNPC1 | |
| SCHEMBL12061928 | 0.85 | MAPT (0.40) | TSHRLMNAMAPTPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | ARDELYX, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11312685-B2 | Targeting nanoparticles | TEXAS HEART INSTITUTE (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
| US-20210188774-A1 | Targeting Nanoparticles | TEXAS CHILDREN'S HOSPITAL | 2021-06-24 | — | — | US | disclosed |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20190275028-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10376481-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-9932331-B2 | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-04-03 | — | — | US | disclosed |
| US-9932331-B2 | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-04-03 | — | — | US | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2017-07-27 | — | — | US | disclosed |
| EP-2094660-A2 | IMMUNOCHEMICALLY EQUIVALENT HIV DRUG ANALOGS | Roche Diagnostics GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008052737-A2 | IMMUNOCHEMICALLY EQUIVALENT HIV DRUG ANALOGS | ROCHE DIAGNOSTICS GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10376481-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP2 | TSHR 688/4885LMNA 3770/4885MAPT 4333/4885 |
| US-20210188774-A1 | Targeting Nanoparticles | PHOSPHO1, CD47, ITGB3 | TSHR 1663/4885LMNA 833/4885MAPT 3113/4885 |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | TSHR 3700/4885LMNA 3836/4885MAPT 2288/4885 |
| US-20190275028-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | TSHR 3112/4885LMNA 4327/4885MAPT 4323/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | TSHR 667/4885LMNA 1098/4885MAPT 3747/4885 |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | HSD11B2, HSD11B1, HSD3B2 | TSHR 1541/4885LMNA 2542/4885MAPT 3787/4885 |
| US-20170210736-A1 | PHENYL TETRAHYDROISOQUINOLINE COMPOUND SUBSTITUTED WITH HETEROARYL | NHERF1, SLC9A3, SLC26A3 | TSHR 850/4885LMNA 3991/4885MAPT 4209/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | TSHR 3700/4885LMNA 3836/4885MAPT 2288/4885 |
| US-11312685-B2 | Targeting nanoparticles | PHOSPHO1, CD47, ITGB3 | TSHR 1663/4885LMNA 833/4885MAPT 3113/4885 |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | TSHR 3112/4885LMNA 4327/4885MAPT 4323/4885 |
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | TSHR 2822/4885LMNA 419/4885MAPT 3994/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | TSHR 772/4885LMNA 3455/4885MAPT 3972/4885 |
| US-20210186953-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | TSHR 3112/4885LMNA 4327/4885MAPT 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.